Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07332455 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 11 → 16 locations
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 5 entries
  2. Study sites: 9 to 11v6
  3. Study sites: 8 to 9v5
  4. Study sites: 6 to 8v4
  5. Trial sites expanded: 3 → 6 locationsv3
  6. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 3
    • Primary completion date: Apr 12, 2028 to Mar 24, 2028
    • Study completion date: Apr 12, 2030 to Mar 26, 2030
    • Start date changed from estimate of Feb 27, 2026 to Feb 10, 2026
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.
Trial Details
NCT Number NCT07332455
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Neoplasms, Prostate
Related terms Prostatic Neoplasms
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov